The new understanding of molecular events that drive the various forms of amyloidosis has led to the expansion of therapeutic options to prevent end-stage disease or even offer a cure, which has ...

AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of a couple of months.